|Videos|January 20, 2021
Role of PARP Inhibition in Recurrent Ovarian Cancer
Author(s)Thomas Herzog, MD
Advertisement
Episodes in this series
Advertisement
Related to this article
New analyses from the RAMP 201 trial demonstrated responses in KRAS wild-type recurrent LGSOC with avutometinib plus defactinib.
Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.
Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
2
Clinical Applications and the Future of Remote Endovascular Procedures
3
Building a Low-Dose Radiation Therapy Program for Benign Disease
4
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
5